Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its allergy management, anti-diarrheals, antiemetic, antibiotic, cardiology, consumer healthcare, diabetes, and emergency care products under Flagyl, Clexane, Lantus, Amaryl, Claforan, Haemaccel, Secnidazole forte, Rulid, Targocid, Tavanic, Tarivid, Aventriax, Stemetil, Lasix, Winstor, Tritace, Cordarone, CoAprovel, Aprovel, CoPlavix, Selsun Blue, Apidra, Toujeo, Soliqua, Daonil, Neodipar, Enterogermina, and Plavix brands. The company was formerly known as Sanofi-Aventis Pakistan Limited and changed its name to Hoechst Pakistan Limited in September 2023. Hoechst Pakistan Limited was incorporated in 1967 and is headquartered in Karachi, Pakistan.
Metrics to compare | HOEC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHOECPeersSector | |
---|---|---|---|---|
P/E Ratio | 14.0x | 21.7x | −0.5x | |
PEG Ratio | 0.14 | 0.02 | 0.00 | |
Price/Book | 3.9x | 3.2x | 2.6x | |
Price / LTM Sales | 1.0x | 1.7x | 3.3x | |
Upside (Analyst Target) | - | 27.1% | 43.4% | |
Fair Value Upside | Unlock | 12.6% | 7.1% | Unlock |